Case Overview

The Parties

Patents at Issue

This case involved two U.S. patents covering peripheral neurostimulation methods and devices in the rapidly developing and commercially competitive area of medical device IP.

• • US10786669B2 — Directed at peripheral neurostimulation technology, broadly covering methods and apparatuses for stimulating peripheral nerves using electromagnetic or electrical means.
• • US11628300B2 — A continuation-family patent extending claim coverage over related neurostimulation systems and methods.
• • Both patents pertain to — Wearable neurostimulation patent infringement.

The Verdict & Legal Analysis

Outcome

On July 12, 2024, EMKinetics filed a Notice of Voluntary Dismissal with Prejudice pursuant to Federal Rule of Civil Procedure 41(a)(1)(A)(i). Because Cala Health had not yet served an answer or a motion for summary judgment, the dismissal was self-executing — no court order was required. Critically, the filing specified that each party shall bear its own attorneys’ fees, costs, and expenses, expressly waiving any entitlement to fee recovery. No damages were awarded, and no injunctive relief was issued.

Procedural Significance of Rule 41(a)(1)(A)(i)

Rule 41(a)(1)(A)(i) permits a plaintiff to dismiss an action without a court order by filing a notice of dismissal before the opposing party serves an answer or a motion for summary judgment. The dismissal with prejudice is the operationally significant element here: unlike a without-prejudice dismissal, EMKinetics has permanently relinquished its right to re-file these same claims against Cala Health on the same patents. This is not a procedural housekeeping measure — it is a binding, final resolution. The mutual fee waiver further signals a negotiated exit rather than a unilateral capitulation. In purely adversarial dismissals, plaintiffs rarely voluntarily forgo any fee entitlement unless a broader agreement — whether a license, cross-license, or covenant not to sue — has been reached privately.

What the Dismissal May Signal

While the specific terms of any inter-party agreement are not publicly disclosed, several strategic scenarios are plausible: (1) **Negotiated License or Settlement:** The parties may have reached a licensing arrangement or financial settlement during the pre-answer period, with the dismissal formalizing that agreement’s IP terms. (2) **Covenant Not to Sue:** Cala Health may have received a covenant not to sue in exchange for concessions or consideration not reflected in the public record. (3) **Plaintiff’s Litigation Risk Re-Assessment:** Following the filing, EMKinetics or its counsel may have identified claim construction vulnerabilities, prior art risks to patent validity, or infringement proof challenges that diminished the merits calculus of continued litigation.

Legal Significance

The case does not establish a judicial precedent — no claim construction orders, validity rulings, or infringement analyses were issued. However, its significance lies in what it reveals about assertion strategy in the wearable neurostimulation space: patent holders in this sector face commercially entrenched defendants with regulatory-cleared products and well-resourced legal teams, making pre-answer resolution a pragmatically attractive outcome on both sides.

Strategic Takeaways

For Patent Holders

Early-stage dismissals with prejudice represent a permanent foreclosure of claims. Plaintiffs must conduct rigorous pre-filing infringement and validity analysis — particularly for continuation patents where claim scope may be narrowed relative to prosecution history.

For Accused Infringers

Retaining experienced local Delaware counsel immediately upon service is critical. The pre-answer period is strategically decisive: defendants who signal strong invalidity or non-infringement positions early may accelerate favorable resolution.

For R&D Teams

Freedom-to-operate (FTO) analysis for wearable neurostimulation products must account for continuation patent families — both US10786669B2 and US11628300B2 share a common technological lineage. Monitoring continuation filings from active assertion portfolios is essential competitive intelligence.